Cat Vaccine-Associated Sarcoma Prevention and Management

Vaccine-associated sarcoma is a rare but serious complication of vaccination in cats that requires aggressive management and informed prevention strategies.

Key Facts

Vaccine-associated sarcoma (VAS) is a malignant soft tissue sarcoma developing at vaccination sites in cats
Incidence is estimated at 1-4 per 10,000 vaccinations, but the exact rate remains debated
The inflammatory response to vaccine adjuvants is thought to trigger malignant transformation in predisposed cats
Best practice vaccination sites have shifted from scruff-of-neck to distal limbs and tail base to allow radical excision if needed
VAS recurs rapidly after inadequate excision - margins of 5 cm laterally and 2 fascial planes deep are recommended
Adjuvanted rabies and FeLV vaccines have historically been most associated with VAS, though all vaccines carry some risk
Non-adjuvanted recombinant vaccines (PUREVAX rabies) were developed partly to reduce VAS risk

Welfare Considerations

VAS is locally aggressive and metastasizes to the lungs in approximately 20-30% of cases. Initial inadequate excision allows rapid local recurrence, requiring repeated surgeries with worsening prognosis. The welfare harm of multiple surgeries for recurrent VAS makes appropriate initial management critically important. Vaccination remains essential - the risks of rabies and FeLV far outweigh VAS risk when vaccines are given appropriately.

What You Can Do

Ask your vet about using non-adjuvanted vaccines (PUREVAX rabies) where available to reduce VAS risk
Ensure vaccination sites are documented and rotate sites as recommended
Inspect vaccination sites monthly for lumps - any lump persisting more than 4 weeks after vaccination should be evaluated
Consent to aggressive initial surgery if VAS is diagnosed - inadequate margins cause rapid recurrence
Request oncology referral for any confirmed VAS - this tumor requires specialist-level management